spironolactone has been researched along with cysteine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Couette, B; Fagart, J; Rafestin-Oblin, ME; Souque, A | 1 |
| Chan, SY; Handy, DE; Leopold, JA; Loscalzo, J; Mahoney, CE; Maron, BA; White, K; Zhang, YY | 1 |
1 review(s) available for spironolactone and cysteine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for spironolactone and cysteine
| Article | Year |
|---|---|
Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor.
Topics: Aldosterone; Cell-Free System; Cysteine; Humans; Kinetics; Methyl Methanesulfonate; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Protein Binding; Receptors, Mineralocorticoid; Recombinant Proteins; Spironolactone; Sulfhydryl Reagents | 1996 |
Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
Topics: Aldosterone; Animals; Cells, Cultured; Cysteine; Disease Models, Animal; Endothelial Cells; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxidative Stress; Pulmonary Artery; Pulmonary Wedge Pressure; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B; Spironolactone; Sulfhydryl Compounds | 2012 |